Anti-LRRK2/Dardarin, C-Terminus Antibody

<strong>Anti-LRRK2/Dardarin, C-Terminus Antibody</strong>_x000D_ <strong>Catalog number:</strong> B2014880_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 50 uL_x000D_ <strong>Molecular Weight or Concentration:</strong> &gt;200_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20°C_x000D_ <strong>Keywords:</strong> Leucine-rich repeat serine/threonine-protein kinase 2 (EC 2.7.11.1) (Dardarin)_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Santpere G, Ferrer I. LRRK2 and neurodegeneration Acta Neuropathol. 2009 Mar;117(3):227-46._x000D_ 2: Davies P, Hinkle KM, Sukar NN, Sepulveda B, Mesias R, Serrano G, Alessi DR, Beach TG, Benson DL, White CL, Cowell RM, Das SS, West AB, Melrose HL. Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies Biochem J. 2013 Jul 1;453(1):101-13._x000D_ 3: Dong CZ, Bruzzoni-Giovanelli H, Yu Y, Dorgham K, Parizot C, Zini JM, Brossas JY, Tuffery P, Rebollo A. Identification of peptides interfering with the LRRK2/PP1 interaction PLoS One. 2020 Aug 13;15(8):e0237110._x000D_ 4: Zhu X, Babar A, Siedlak SL, Yang Q, Ito G, Iwatsubo T, Smith MA, Perry G, Chen SG. LRRK2 in Parkinson's disease and dementia with Lewy bodies Mol Neurodegener. 2006 Nov 30;1:17._x000D_ 5: Delbroek L, Van Kolen K, Steegmans L, da Cunha R, Mandemakers W, Daneels G, De Bock PJ, Zhang J, Gevaert K, De Strooper B, Alessi DR, Verstreken P, Moechars DW. Development of an enzyme-linked immunosorbent assay for detection of cellular and in vivo LRRK2 S935 phosphorylation J Pharm Biomed Anal. 2013 Mar 25;76:49-58._x000D_ 6: Maekawa T, Shimayama H, Tsushima H, Kawakami F, Kawashima R, Kubo M, Ichikawa T. LRRK2: An Emerging New Molecule in the Enteric Neuronal System That Quantitatively Regulates Neuronal Peptides and IgA in the Gut Dig Dis Sci. 2017 Apr;62(4):903-912._x000D_ 7: Gillardon F, Kremmer E, Froehlich T, Ueffing M, Hengerer B, Gloeckner CJ. ATP-competitive LRRK2 inhibitors interfere with monoclonal antibody binding to the kinase domain of LRRK2 under native conditions. A method to directly monitor the active conformation of LRRK2? J Neurosci Methods. 2013 Mar 30;214(1):62-8._x000D_ 8: Hakimi M, Selvanantham T, Swinton E, Padmore RF, Tong Y, Kabbach G, Venderova K, Girardin SE, Bulman DE, Scherzer CR, LaVoie MJ, Gris D, Park DS, Angel JB, Shen J, Philpott DJ, Schlossmacher MG. Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures J Neural Transm (Vienna). 2011 May;118(5):795-808._x000D_ 9: Vitte J, Traver S, Maués De Paula A, Lesage S, Rovelli G, Corti O, Duyckaerts C, Brice A. Leucine-rich repeat kinase 2 is associated with the endoplasmic reticulum in dopaminergic neurons and accumulates in the core of Lewy bodies in Parkinson disease J Neuropathol Exp Neurol. 2010 Sep;69(9):959-72._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/19680143">10: Higashi S, Moore DJ, Yamamoto R, Minegishi M, Sato K, Togo T, Katsuse O, Uchikado H, Furukawa Y, Hino H, Kosaka K, Emson PC, Wada K, Dawson VL, Dawson TM, Arai H, Iseki E. Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease J Neuropathol Exp Neurol. 2009 Sep;68(9):994-1005. </a>_x000D_ _x000D_ <strong>Products Related to Anti-LRRK2/Dardarin, C-Terminus Antibody can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>